Drug Index


Mechanism :

Morphine, a pure opioid agonist, is relatively selective for the mu receptor, although it can interact with other opioid receptors at higher doses. In addition to analgesia, the widely diverse effects of morphine include drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting and alterations of the endocrine and autonomic nervous system.

Indication :

  • Pain-acute/post and peri-operative
  • Sedation in ICU
  • Chronic pain
  • Palliative care
  • Cyanotic spell

Contraindications :

Contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product, in patients with respiratory depression in the absence of resuscitative equipment, in patients with acute or severe bronchial asthma and in any patient, who has or is suspected of having paralytic ileus.

Dosing :

Analgesia, Cyanotic spell: IM/IV/SC
Neonates: 0.3-1.2 mg/kg/day divided every 4 hours or continuous infusion 0.005-0.03 mg/kg/hour.
Infants and children <12 years: 0.05-0.2 mg/kg/dose every 2-4 hours or oral: 0.2-0.4 mg/kg/dose every 4-6 hours.
>12 years: 3-4 mg IV. May repeat after 5 min if required.
Postoperative pain:
0.01-0.04 mg/kg/ hour by IV infusion.
Sickle cell disease, cancer pain:
0.04-0.07 mg/kg/ hour by IV infusion.

Adverse Effect :

Respiratory depression, apnoea, vomiting, nausea, death, dehydration, dyspnea, sepsis, circulatory depression, shock, cardiac arrest, pruritus, urinary retention, headache, somnolence.

Interaction :

CNS Depressants: The concurrent use of other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma.
Muscle Relaxants: Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
Mixed Agonist/Antagonist Opioid Analgesics: Mixed agonist/antagonist analgesics (i.e. pentazocine, nalbuphine and butorphanol) should not be administered to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.
Monoamine Oxidase Inhibitors (MAOIs): MAOIs markedly potentiate the action of morphine.
Cimetidine: Concomitant administration of morphine and cimetidine has been reported to precipitate apnea, confusion and muscle twitching.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-5075% of normal dose
10-20Use small doses, e.g. 2.5–5 mg and extended dosing intervals. Titrate according to response
<10Use small doses, e.g. 1.25–2.5 mg and extended dosing intervals. Titrate according to response

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDDialysed – active metabolite removed significantly. Dose as in GFR<10 mL/min
HDF/High fluxDialysed – active metabolite removed significantly. Dose as in GFR<10 mL/min
CAV/VVHDDialysed. Dose as in GFR=10– 20 mL/min

Hepatic Dose :

Mild and moderate hepatic impairment: Begin with a lower dose and titrate slowly while monitoring for sedation, respiratory depression and hypotension.
Severe hepatic impairment: Use is contraindicated as it can precipitate coma.
Morphine sulfate extended-release liposome injection, which is only used as a single epidural dose can be given without dose adjustment in hepatic impairment.
01/15/2021 10:01:16 Morphine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0